%0 Journal Article %A Regine Kluge %A Tim Wittig %A Thomas W. Georgi %A Lars Kurch %A Osama Sabri %A W. Hamish Wallace %A Tomasz Klekawka %A Ana Fernández-Teijeiro %A Francesco Ceppi %A Jonas Karlén %A Jane Pears %A Michaela Cepelová %A Alexander Fosså %A Auke Beishuizen %A Lisa Lyngsie Hjalgrim %A Dieter Körholz %A Christine Mauz-Körholz %A Dirk Hasenclever %T Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease %D 2021 %R 10.2967/jnumed.120.247924 %J Journal of Nuclear Medicine %P 338-341 %V 62 %N 3 %X In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1–3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria. %U https://jnm.snmjournals.org/content/jnumed/62/3/338.full.pdf